Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025 Acurx provided groundbreaking findings on its DNA pol IIIC inhibitor, ibezapolstat, which shows selective antibacterial properties, at IDWeek 2025.

Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025 #USA #Atlanta #Ibezapolstat #Acurx_Pharmaceuticals #DNA_pol_IIIC

Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference Acurx Pharmaceuticals showcased significant findings from its research on novel antibiotics at a leading scientific conference, advancing the fight against persistent infections.

Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference #United_States #New_York #Ibezapolstat #Acurx_Pharmaceuticals #DNA_pol_IIIC